Mexico is one of the fastest growing pharmaceutical markets in the world valued at over $13.5 billion and growing at 9-10 per cent annually.

Lupin has acquired 100 per cent equity stake in Laboratorios Grin, S.A. De C.V., Mexico, subject to certain closing conditions, for an unspecified amount. The acquisition marks Lupin’s entry into the high-growth Mexican and the larger Latin American pharmaceuticals market. “We see a lot of synergies in this acquisition and plan to bring our ophthalmic pipeline to build the Grin business as well as leverage their commercial presence to enter other promising therapy segments,” Vinita Gupta, Chief Executive Officer, Lupin, said.


Lupin buys Netherlands firmFebruary 3, 2014

Lupin launches HIV drug in the U.S.December 18, 2013

More In: Industry | Business